Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 52 (7), 941-949

Carmustine Replacement in Intensive Chemotherapy Preceding Reinjection of Autologous HSCs in Hodgkin and non-Hodgkin Lymphoma: A Review

Affiliations
Review

Carmustine Replacement in Intensive Chemotherapy Preceding Reinjection of Autologous HSCs in Hodgkin and non-Hodgkin Lymphoma: A Review

G Damaj et al. Bone Marrow Transplant.

Abstract

High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM. In addition to these two combinations, the present manuscript also summarizes data reported for other conditioning combinations. Owing to the lack of prospective and comparative studies, a comparison of the toxicities and medicoeconomical profiles of these treatments is warranted to identify effective replacements for BCNU-based conditioning.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):21-7 - PubMed
    1. Cancer. 2004 Jun 15;100(12):2607-12 - PubMed
    1. Biol Blood Marrow Transplant. 2007 Jan;13(1):56-64 - PubMed
    1. Bone Marrow Transplant. 2016 Feb;51(2):319-21 - PubMed
    1. Br J Cancer. 2007 Jun 4;96(11):1692-8 - PubMed

MeSH terms

Supplementary concepts

Feedback